Belvedere Trading
CORT icon

Belvedere Trading’s Corcept Therapeutics CORT Stock Holding History

Belvedere Trading’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-12,624
Closed -$293K – 398
2022
Q1 		$293K Buy
+12,624
New +$269K 0.01% 177

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Belvedere Trading's CORT Position: Q2 2022 in Review

Belvedere Trading sold out of Corcept Therapeutics (CORT) in Q2 2022, closing a stake of 12,624 shares — an estimated $293K sold.

Belvedere Trading first reported a position in CORT in Q1 2022 and held it in 1 quarter. The position peaked at $293K in Q1 2022. 225 funds tracked by Wall St. Rank hold CORT as of Q2 2022.

  • Belvedere Trading reported no remaining Corcept Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Belvedere Trading sold 12,624 Corcept Therapeutics shares in Q2 2022, an estimated $293K.
  • Belvedere Trading first reported a position in Corcept Therapeutics in Q1 2022 and held it in 1 quarter.
  • Belvedere Trading's Corcept Therapeutics position peaked at $293K in Q1 2022.
  • 225 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2022.

Based on Belvedere Trading's 13F filing for Q2 2022, filed 21 Jul 2022.